WeVote
Log In

Bill

Bill

HR 843

Prompt Approval of Safe Generic Drugs Act

119th Congress Introduced by Nanette Barragán

HR 843 speeds up the approval of generic drugs, boosting competition, lowering prices, and improving access to essential medications for consumers.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 843

Summary of HR 843: Prompt Approval of Safe Generic Drugs Act

Bill Overview

  • Bill Number: HR 843
  • Title: Prompt Approval of Safe Generic Drugs Act
  • Status: Introduced in House
  • Introduced Date: January 31, 2025
  • Classification: Bill

Purpose and Intent

The Prompt Approval of Safe Generic Drugs Act aims to streamline the approval process for generic drugs, ensuring that safe and effective alternatives to brand-name medications are available to consumers in a timely manner. The bill seeks to enhance competition in the pharmaceutical market, potentially lowering drug prices and improving access to essential medications.

Key Provisions

The bill includes several significant provisions designed to expedite the approval process for generic drugs:

  1. Accelerated Review Process:

    • Establishes a framework for expedited review of generic drug applications, particularly for medications that have limited competition or are critical for public health.

  2. Increased Transparency:

    • Mandates the U.S. Food and Drug Administration (FDA) to provide clearer guidelines and timelines for the approval process, ensuring that applicants are informed about the status of their submissions.

  3. Support for Small Manufacturers:

    • Introduces measures to assist small pharmaceutical companies in navigating the approval process, including technical assistance and reduced fees.

  4. Safety and Efficacy Standards:

    • Maintains rigorous safety and efficacy standards for all generic drugs, ensuring that expedited approvals do not compromise public health.

Impact

The Prompt Approval of Safe Generic Drugs Act is expected to have a broad impact on various stakeholders:

  • Consumers: Increased availability of generic drugs may lead to lower prices and improved access to necessary medications.
  • Pharmaceutical Companies: The bill may encourage more companies, especially smaller manufacturers, to enter the market, fostering competition.
  • Healthcare Providers: With more options available, healthcare providers may have greater flexibility in prescribing medications.

Procedural Aspects

  • The bill was introduced and referred to the House Committee on Energy and Commerce on January 31, 2025. Further legislative actions will determine its progression through Congress.

Conclusion

HR 843 represents a significant effort to enhance the availability of generic drugs in the U.S. healthcare system. By streamlining the approval process and supporting small manufacturers, the bill aims to foster competition and improve access to affordable medications for consumers.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.